Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. For patients with refractory acute respiratory distress syndrome (ARDS) due to COVID-19 infections, ...

SARS-CoV-2, the virus that causes COVID-19, can damage the heart even without directly infecting the heart tissue, a new study has found. The research specifically looked at damage to the hearts of ...

With vaccination rates increasing and new infections declining, we all hope the worst of the COVID-19 pandemic is over (fingers crossed really tight). Regardless, the post–COVID-19 syndrome pandemic ...

In a recent study published in the journal Circulation, researchers investigate the inflammatory response to acute respiratory distress syndrome (ARDS) within the heart. Study: Virus-Induced Acute ...

Promising trial results indicate that a new type of cell therapy could improve the prognosis of those who are critically ill with acute respiratory distress syndrome (ARDS) resulting from severe Covid ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed high lysolipid levels in those with acute respiratory distress syndrome (ARDS), which may ...

Inhaled sevoflurane significantly reduced ventilator-free days and 90-day survival versus IV propofol in moderate to severe ARDS. Inhaled volatile sedatives grew in popularity for prolonged use in ...

This Image shows the lung surfactant, a complex composed of fats and proteins generated in the lungs, after being exposed to the lysolipid in water where the bright red spots indicate the lysolipid ...

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is ...

During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), ...